INRLF
$5.9
$
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.
Next Earnings
2026-02-25
Beta
1.203
Average Volume
Market Cap
Last Dividend
CIK
ISIN
FR0004056851
CUSIP
CEO
Thomas Lingelbach
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
713
IPO Date
2010-04-23
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| VALNEVA Declaration of shares and voting rights: January 31, 2026 | Registered office: Îlot Saint-Joseph Bureaux Convergence – Bât. A, 12 ter Quai Perrache – 69002 Lyon. | GlobeNewsWire | 2026-02-06 02:30:00 |
| Valneva withdraws application for standard US approval of its chikungunya shot | French drugmaker Valneva said on Monday it has voluntarily withdrawn its application seeking standard approval of its chikungunya vaccine in the United States after the FDA suspended the shot's license in August, citing safety concerns. | Reuters | 2026-01-19 14:00:09 |
| Valneva SE - Declaration of voting rights - December 2025 | Registered office: Îlot Saint Joseph Bureaux Convergence – 12T Quai Perrache – 69002 Lyon | GlobeNewsWire | 2026-01-08 12:30:00 |
| Valneva and Serum Institute of India Announce Discontinuation of Chikungunya Vaccine License Agreement | Saint-Herblain (France), Pune, (India), December 31, 2025 – Valneva SE (“Valneva” or “the Company”), a specialty vaccine company, and Serum Institute of India (SII), a Cyrus Poonawalla Group company today announced that they have mutually agreed to discontinue their license agreement for Valneva's single-shot chikungunya vaccine. | GlobeNewsWire | 2025-12-31 11:45:00 |
| VALNEVA Declaration of shares and voting rights: November 30, 2025 | Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France). | GlobeNewsWire | 2025-12-05 12:34:00 |
| Valneva Posts Positive Lyme Vaccine Booster Results — Pfizer Targeting 2026 Regulatory Filings | Valneva SE (NASDAQ: VALN) shared final immunogenicity and safety data on Wednesday from the Phase 2 study, VLA15-221, of the Lyme disease vaccine candidate, VLA15. | Benzinga | 2025-11-26 12:30:25 |
| Valneva Shares Rise on Positive Data from Lyme Disease Vaccine Study | Valneva said that antibody levels remained well above baseline across all six Lyme disease serotypes and all age groups in the trial. | WSJ | 2025-11-26 06:37:00 |
Algorithm Performance
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|